MYD88 and primary central nervous system lymphoma: Multiple studies have demonstrated the utility of ddPCR in detecting canonical recurrent point mutations, specifically MYD88 L265P (present in over 80% of PCNSL tumors) in CSF-derived ctDNA samples from primary and secondary CNS lymphoma patients [36].